Sticherling, Michael http://orcid.org/0000-0001-9396-3938
Nikkels, Arjen F.
Hamza, Ashraf M.
Kwong, Pearl
Szepietowski, Jacek C.
El Sayed, Mahira
Ghislain, Pierre-Dominique
Khotko, Alkes A.
Patekar, Manmath
Ortmann, Christine-Elke
Forrer, Pascal
Papanastasiou, Philemon
Keefe, Deborah
Clinical trials referenced in this document:
Documents that mention this clinical trial
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
https://doi.org/10.1007/s40257-023-00782-8
Documents that mention this clinical trial
Secukinumab in Pediatric Patients with Plaque Psoriasis: Pooled Safety Analysis from Two Phase 3 Randomized Clinical Trials
https://doi.org/10.1007/s40257-023-00782-8
Funding for this research was provided by:
Novartis Pharma AG, Basel, Switzerland
Friedrich-Alexander-Universität Erlangen-Nürnberg
Article History
Accepted: 3 April 2023
First Online: 21 June 2023
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. The study was funded by Novartis Pharma AG, Basel, Switzerland.
: <i>Michael Sticherling</i> is an investigator, speaker, consultant/advisory board member, and participated in clinical trials with the following companies: AbbVie, Amgen, BMS, Celgene, Galderma, GSK, Janssen Cilag, Leo, Lilly, MSD, Mundipharma, Novartis, Regeneron, Pfizer, Sanofi, and UCB. <i>Arjen F. Nikkels</i> has nothing to disclosure. <i>Ashraf M. Hamza</i> is a principal investigator for Novartis and speaker for Sanofi and Pfizer. <i>Pearl Kwong</i> is an investigator, speaker, and/or consultant for Pfizer, Eli Lilly, Regeneron Sanofi Genzyme, Ortho, Verrica, Vyne, Journey, Incyte Almirall, Novartis, Amgen/Celgene, AbbVie, Dermira, Galderma, Castle Creek Biosciences, and Arcutis. <i>Jacek C. Szepietowski</i> is an advisory board member of AbbVie, LEO Pharma, Novartis, Pierre-Fabre, Menlo Therapeutics, Sienna Biopharmaceuticals, and Trevi Therapeutics; principal investigator for AbbVie, Novartis, Menlo Therapeutics, Trevi Therapeutics, Janssen, Merck, Regeneron, Amgen, Boehringer Ingelheim, Galapagos, Galderma, InflaRX, Kymab Ltd., Pfizer, UCB, Helm, and Incyte; and a speaker for AbbVie, Novartis, Janssen, Eli Lilly, Sanofi-Genzyme, Sunfarm, and Berlin-Chemie Menarini. <i>Mahira El Sayed</i> is a speaker and advisory board member of AbbVie, Novartis, Janssen, Amgen, Sandoz, Sanofi, Pfizer, and Eli Lilly. <i>Pierre-Dominique Ghislain</i> is receiving consultancy and fees as speaker, investigator, or grants for Pfizer, MSD, AbbVie, Janssen, Serono, Leo, Novartis, UCB, Amgen, Eli Lilly, Galderma, BMS, Meda, Maruho, Flen, Menarini, Almirall, PellePharm, and Viatris. <i>Alkes A Khotko</i> is an investigator in sponsored clinical trials of AbbVie, Novartis, Janssen, Amgen, Sanofi, Eli Lilly, Biocad, Akrikhin, Alfasigma S.p.A., OOO Pharmapark, Argenx BV, and Bristol Myers Squibb. <i>Manmath Patekar</i>, <i>Christine-Elke Ortmann</i>, <i>Philemon Papanastasiou</i>, <i>Pascal Forrer</i>, and <i>Deborah Keefe</i> are employees of Novartis.
: The clinical trials were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice (GCP) and in compliance with all federal, local, or regional requirements.
: An informed consent form approved by a study site’s institutional review board was signed by the participants or legal representative and the investigator before enrollment of participants.
: Not applicable.
: The datasets generated and/or analyzed during the current study are not publicly available. Novartis is committed to sharing with qualified external researchers access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved on the basis of scientific merit. All data provided are anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The data may be requested from the corresponding author of the article.
: Not applicable.
: Concept and design: MS, AFN, AMH, PK, JCS, MES, P-DG, AAK, MP, PP, PF, DK. Acquisition, analysis, or interpretation of data: All authors. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: All authors. Statistical analysis: C-EO. Administrative, supervision, technical, or material support: All authors.